Search

Your search keyword '"Pérez-Molina, Inmaculada"' showing total 10 results
Start Over Author "Pérez-Molina, Inmaculada"
10 results on '"Pérez-Molina, Inmaculada"'

1. Central and peripheral myeloid-derived suppressor cell-like cells are closely related to the clinical severity of multiple sclerosis

Author

Ortega, María Cristina, Lebrón-Galán, Rafael, Machín-Díaz, Isabel, Naughton, Michelle, Pérez-Molina, Inmaculada, García-Arocha, Jennifer, Garcia-Dominguez, Jose Manuel, Goicoechea-Briceño, Haydee, Vila-del Sol, Virginia, Quintanero-Casero, Víctor, García-Montero, Rosa, Galán, Victoria, Calahorra, Leticia, Camacho-Toledano, Celia, Martínez-Ginés, María Luisa, Fitzgerald, Denise C., and Clemente, Diego

Published
2023
Full Text
View/download PDF

2. SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry

Author

Arrambide, Georgina, Llaneza-González, Miguel Ángel, Costa-Frossard França, Lucienne, Meca-Lallana, Virginia, Díaz, Eva Fernández-, Moreno-Torres, Irene, García-Domínguez, Jose Manuel, Ortega-Suero, Gloria, Ayuso-Peralta, Lucía, Gómez-Moreno, Mayra, Sotoca-Fernández, Javier J., Caminero-Rodríguez, Ana Belén, Rodríguez de Antonio, Luis A., Corujo-Suárez, Marcial, Otano-Martínez, María A., Pérez-Miralles, Francisco Carlos, Reyes-Garrido, Virginia, Ayuso-Blanco, Teresa, Balseiro-Gómez, José Jesús, Muñoz-Pasadas, Mercedes, Pérez-Molina, Inmaculada, Arnal-García, Carmen, Domingo-Santos, Ángela, Guijarro-Castro, Cristina, Íñiguez-Martínez, Cristina, Téllez Lara, Nieves, Castellanos-Pinedo, Fernando, Castillo-Triviño, Tamara, Cerdán-Santacruz, Debora María, Pérez-Sempere, Ángel, Torres, Berta Sebastián, Álvarez de Arcaya, Amaya, Costa-Arpín, Eva, Durán-Ferreras, Eduardo, Fragoso-Martínez, Marta, González-Platas, Montserrat, Landete Pascual, Lamberto, Millán-Pascual, Jorge, Oreja-Guevara, Celia, and Meca-Lallana, José E.

Published
2021
Full Text
View/download PDF

3. Myeloid-Derived Suppressor Cells are relevant factors to predict the severity of multiple sclerosis

Author

Ortega, María Cristina, primary, Lebrón-Galán, Rafael, additional, Machín-Díaz, Isabel, additional, Naughton, Michelle, additional, Pérez-Molina, Inmaculada, additional, García-Arocha, Jennifer, additional, García-Domínguez, Jose Manuel, additional, Goicoechea-Briceño, Haydee, additional, Vila-del Sol, Virginia, additional, Quintanero-Casero, Víctor, additional, García-Montero, Rosa, additional, Galán, Victoria, additional, Camacho-Toledano, Celia, additional, Martínez-Ginés, María Luisa, additional, Fitzgerald, Denise C., additional, and Clemente, Diego, additional

Published
2022
Full Text
View/download PDF

4. SARS-CoV-2 Infection in Multiple Sclerosis

Author

Arrambide, Georgina, Llaneza-González, Miguel Ángel, Costa-Frossard França, Lucienne, Meca-Lallana, Virginia, Díaz, Eva Fernández, Moreno-Torres, Irene, García-Domínguez, Jose Manuel, Ortega-Suero, Gloria, Ayuso-Peralta, Lucía, Gómez-Moreno, Mayra, Sotoca Fernández, Javier, Caminero-Rodríguez, Ana Belén, Rodríguez de Antonio, Luis A., Corujo-Suárez, Marcial, Otano-Martínez, María A., Pérez-Miralles, Francisco Carlos, Reyes-Garrido, Virginia, Ayuso-Blanco, Teresa, Balseiro-Gómez, José, Muñoz-Pasadas, Mercedes, Pérez-Molina, Inmaculada, Domingo-Santos, Ángela, Guijarro-Castro, Cristina, Íñiguez-Martínez, Cristina, Téllez Lara, Nieves, Castellanos-Pinedo, Fernando, Castillo-Triviño, Tamara, Cerdán-Santacruz, Debora María, Torres, Berta Sebastián, Álvarez de Arcaya, Amaya, Costa-Arpín, Eva, Durán-Ferreras, Eduardo, González-Platas, Montserrat, Landete Pascual, Lamberto, Millán-Pascual, Jorge, Oreja-Guevara, Celia, and Universitat Autònoma de Barcelona

Abstract

To understand COVID-19 characteristics in people with multiple sclerosis (MS) and identify high-risk individuals due to their immunocompromised state resulting from the use of disease-modifying treatments. Retrospective and multicenter registry in patients with MS with suspected or confirmed COVID-19 diagnosis and available disease course (mild = ambulatory; severe = hospitalization; and critical = intensive care unit/death). Cases were analyzed for associations between MS characteristics and COVID-19 course and for identifying risk factors for a fatal outcome. Of the 326 patients analyzed, 120 were cases confirmed by real-time PCR, 34 by a serologic test, and 205 were suspected. Sixty-nine patients (21.3%) developed severe infection, 10 (3%) critical, and 7 (2.1%) died. Ambulatory patients were higher in relapsing MS forms, treated with injectables and oral first-line agents, whereas more severe cases were observed in patients on pulsed immunosuppressors and critical cases among patients with no therapy. Severe and critical infections were more likely to affect older males with comorbidities, with progressive MS forms, a longer disease course, and higher disability. Fifteen of 33 patients treated with rituximab were hospitalized. Four deceased patients have progressive MS, 5 were not receiving MS therapy, and 2 were treated (natalizumab and rituximab). Multivariate analysis showed age (OR 1.09, 95% CI, 1.04-1.17) as the only independent risk factor for a fatal outcome. This study has not demonstrated the presumed critical role of MS therapy in the course of COVID-19 but evidenced that people with MS with advanced age and disease, in progressive course, and those who are more disabled have a higher probability of severe and even fatal disease

Published
2021

5. MYELOID-DERIVED SUPPRESSOR CELL BURDEN IN THE CNS AND BLOOD IS ASSOCIATED WITH DISEASE SEVERITY OF MULTIPLE SCLEROSIS PATIENTS

Author

Machin-Diaz, Isabel, Naughton, Michelle, Pérez-Molina, Inmaculada, García-Arocha, Jennifer, García-Domínguez, Jose Manuel, García-Briceño, Haydee, Lebron-Galan, Rafael, Sol, Virginia Vila-Del, Quintanero-Casero, Victor, García-Montero, Rosa, Galan, Victoria, Calahorra, Leticia, Camacho-Toledano, Celia, Martinez-Gines, Maria Luisa, Fitzgerald, Denise, and Clemente, Diego

Published
2023
Full Text
View/download PDF

6. Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study

Author

Oreja-Guevara, Celia, Meca-Lallana, José E., Díaz-Díaz, Judit, Ara, José-Ramón, Hernández Pérez, Miguel Ángel, Gracia Gil, Julia, Alonso Torres, Ana María, Pilo de la Fuente, Belén, Ramió-Torrentà, Lluís, Eichau Madueño, Sara, Gascón-Giménez, Francisco, Casanova, Bonaventura, Martínez-Yélamos, Sergio, Aguado Valcárcel, Marta, Martínez Ginés, Maria Luisa, El Berdei Montero, Yasmina, López Real, Ana María, González-Quintanilla, Vicente, De Torres, Laura, Martínez-Rodríguez, José Enrique, Costa-Frossard, Lucienne, Garcés Redondo, Moisés, Labiano Fontcuberta, Andrés, Castellanos-Pinedo, Fernando, García Merino, Juan Antonio, Muñoz Fernández, Carmen, Castillo-Triviño, Tamara, Meca-Lallana, Virginia, Peña Martínez, Joaquín, Rodríguez-Antigüedad, Alfredo, Prieto González, José María, Agüera Morales, Eduardo, Pérez Molina, Inmaculada, Solar Sánchez, Dulce M, Herrera Varo, Nicolás, Romero Sevilla, Raúl, Gómez Vicente, Lidia, and Río, Jordi

Abstract

•SPMS represents a considerable negative impact on patients’ HRQoL•Unfortunately, there is a lack of data about the impact of SPMS disability on HRQoL•DISCOVER study is an observational, retrospective study in clinical practice in Spain•DISCOVER study assess the impact of SPMS on participants’ functional status and HRQoL•People with SPMS experience a high physical impact, fatigue and cognitive impairment

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results